This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
In semi‑structured interviews with 12 participants from a Phase II randomised controlled trial, ketamine infusions delivered in a supportive clinical setting produced varied acute experiences—including dissociation, ego dissolution and mystical/spiritual states—that participants linked to transformative changes in their relationship with alcohol. The authors conclude these broader psychoactive effects may mediate therapeutic benefit and recommend developing measures that capture the full spectrum of ketamine experiences.
Abstract
Background
The therapeutic benefits of ketamine have been demonstrated for a variety of psychiatric disorders. However, the role of ketamine induced psychoactive experiences in mediating the therapeutic effects is unclear. Despite the growing quantitative research on the efficacy of ketamine treatment, very few studies examined participant experiences of ketamine infusions in a treatment setting.
Aims
The current study aimed to examine participant experiences of ketamine infusions and how these relate to therapeutic mechanisms in a clinical trial setting.
Methods
We conducted semi-structured interviews with 12 participants who received up to three ketamine infusions (0.8 mg/kg) as part of a Phase II double blind, randomised controlled trial. The interviews explored participants' acute experiences of ketamine infusions, experiences of psychotherapy/education, and the lasting effects of the trial. The interviews were transcribed verbatim and analysed using thematic analysis.
Results
Six key themes were identified. (1) Participants reported multifaceted motivations for trial participation. (2) The set and setting was found to be influential in determining acute ketamine experiences. The acute ketamine experiences included: (3) the inherent contradictions of the experience (e.g., dissociation vs feelings of connection), (4) rapidly fluctuating and changing experiences, (5) meaningful, mystical and spiritual experiences. Finally, the final theme (6) relates to the transformational effects of the infusions and the trial.
Conclusion
Provided in a supportive and professional environment, ketamine treatment led to a significant change in relationship with alcohol. Ketamine induced ego dissolution and dissociation were reported to be related to the transformational effects on relationship with alcohol. The extent to which the acute psychoactive effects of ketamine mediate therapeutic effects on drinking outcomes remain to be investigated in the trial data. The acute effects of ketamine reported by our participants transcend its traditional conceptualisation as a “dissociative anaesthetic”; therefore, we suggest the development or use of new measures alongside ketamine infusions to fully capture the spectrum of these effects which may be crucial in its therapeutic and transformative effects.
Research Summary of 'This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders'
Introduction
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist originally developed as an anaesthetic, has attracted renewed interest for treating psychiatric disorders at sub-anaesthetic doses. Previous quantitative work has demonstrated rapid antidepressant and other therapeutic effects and some studies have suggested ketamine can influence substance use outcomes. However, comparatively little qualitative work has examined patients' phenomenological experiences of therapeutic ketamine and how those acute psychoactive effects might relate to clinical change. Existing scales used in ketamine trials emphasise dissociation and may not capture the full range of subjective effects, including mystical, spiritual or awe-related experiences, that could plausibly contribute to therapeutic mechanisms. J. and colleagues set out to explore, through semi-structured qualitative interviews, the retrospective subjective experiences of participants who received at least one ketamine infusion as part of a Phase II randomised controlled trial (the KARE trial) for alcohol use disorder. The study aimed to characterise motivations for participation, the role of set and setting, the nature of acute and subacute ketamine experiences (including perceptual, dissociative and mystical phenomena), and participants' perceptions of lasting or transformational effects on their relationship with alcohol and broader life perspective. The authors frame this work as complementary to quantitative trial outcomes and as a means to inform future measurement and clinical practice in ketamine-assisted treatment.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021). This Is Something That Changed My Life: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.695335
References (34)
Papers cited by this study that are also in Blossom
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Serafini, G., Howland, R. H., Rovedi, F. et al. · Current Neuropharmacology (2014)
Martinotti, G., Pettorruso, M. · Brain Sciences (2021)
Jones, J. L., Mateus, C. F., Malcolm, R. J. et al. · Frontiers in Psychiatry (2018)
Dakwar, E., Levin, F. R., Hart, C. L. et al. · American Journal of Psychiatry (2020)
Ezquerra-Romano, I. I., Lawn, W., Krupitsky, E. M. et al. · Neuropharmacology (2018)
Krupitsky, E. M., Grinenko, A. Y. · Journal of Psychoactive Drugs (1997)
Krupitsky, E. M., Burakov, A. M., Romanova, T. N. et al. · Journal of Substance Abuse Treatment (2002)
Sumner, R. L., Chacko, E., Mcmillan, R. et al. · Journal of Psychopharmacology (2021)
Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)
Show all 34 referencesShow fewer
Dakwar, E., Nunes, E. V., Hart, C. L. et al. · Neuropharmacology (2018)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Nutt, D. J., Carhart-Harris, R. L. · Current Drug Abuse Reviews (2015)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Yaden, D. B., Le Nguyen, K. D., Kern, M. L. et al. · Journal of Humanistic Psychology (2016)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Kirchner, K. · Journal of Psychopharmacology (2014)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Hendricks, P. S. · International Review of Psychiatry (2018)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Van Schalkwyk, G. I., Wilkinson, S. T., Davidson, L. et al. · Journal of Affective Disorders (2018)
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F. et al. · Journal of Affective Disorders (2014)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Cited By (8)
Papers in Blossom that reference this study
Argyri, E. K., Evans, J., Luke, D. et al. · SSRN (2024)
Mathai, D. S., Hilbert, S., Sepeda, N. D. et al. · Psychedelic Medicine (2023)
Hack, L. M., Zhang, X., Heifets, B. D. et al. · Nature Communications (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Mathai, D. S., Nayak, S., Yaden, D. B. et al. · Psychopharmacology (2023)
Lapidos, A., Lopez-Vives, D., Sera, C. E. et al. · Journal of Affective Disorders (2023)
Breeksema, J. J., Niemeijer, A. R., Kuin, B. et al. · Frontiers in Psychiatry (2022)
Keeler, J. L., Treasure, J., Juruena, M. F. et al. · Nutrients (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.